News Articles and Montana BioScience Alliance Newsletters
Inimmune is a leader in the discovery and development of vaccine adjuvants with over 20 years of expertise in their safe and effective use.
The University of Montana was named a top-tier “R1” research institution last year. It was the culmination of a decades-long goal for UM, and the science surge has only gained momentum in the first six months of the 2022-23 fiscal year.
Health care is Montana’s largest industry and is projected to experience more job growth than any other industry in the state over the next eight years. However, with the State employment rate hovering around 2.6%, health care facilities are facing extreme workforce shortages. Because of this high demand for health care workers, Bitterroot Health and Bitterroot College are partnering to address these workforce issues through innovation and collaboration.
Montana State University has joined with a dozen other universities in the region to form a partnership aimed at creating economic development opportunities around emerging high-tech industries.
INDUSTRY Bozeman, a multi-tenant modern office space, has broken ground on an 87,000-square-foot building to be located on the Montana State University Innovation Campus.
Are you working to develop an innovative cancer technology? Take a step forward in your commercialization journey through the newly released FY2024 SBIR Contract Solicitation! This funding opportunity aims to provide early-stage funding to small businesses that are developing cancer technologies in areas defined by the National Cancer Institute.
The U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit.
The PHS 2023-2 omnibus solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications have been released. The first application due date is Tuesday, September 5, 2023.
The panel’s decision moves the U.S. one step closer to making jabs against respiratory syncytial virus available to the public this fall, when the disease typically begins to spread at higher levels.
The biennial report provides a national snapshot of the most pressing current and anticipated talent needs of the nation’s dynamic life science industry. This year’s report distills a set of key themes sourced from 185 executive interviews and nearly 700 survey responses from companies in eighteen states and Puerto Rico, as well as an assessment of nearly 2.8M job postings from life science companies over the last four years.